Key Highlights

  • Danaher (NYSE:DHR) reported on Wednesday, October 21, 2026 that Diagnostics sales rose 17.0%, with acquisitions adding 16.5 points, while core growth in the segment was 0.5% as respiratory testing declined.
  • Group revenue rose 8.5% to USD 6.55 billion, and adjusted diluted EPS of USD 2.11 beat the consensus estimate of USD 1.92, on total core growth of 3.0%.
  • GAAP diluted EPS from continuing operations rose to USD 1.71 from USD 1.27, helped by a discrete tax benefit of USD 263 million, or USD 0.37 per share, mostly from released tax reserves.
  • Free cash flow rose about 19% to USD 1.63 billion, and full-year adjusted EPS guidance rose to USD 8.57 to USD 8.62 from USD 8.45 to USD 8.60.

Where the Growth Came From

Danaher (NYSE:DHR), the Washington, D.C. based life sciences and diagnostics group, reported third-quarter results on Wednesday, October 21, 2026. Revenue rose 8.5% to USD 6.55 billion, but core growth, which strips out acquisitions and currency, was 3.0%, at the top of the 2% to 3% range flagged before results. Excluding respiratory testing, core growth was 5.5%. Biotechnology sales rose 0.5% on 5.0% core growth, and Life Sciences rose 4.0% on 4.5% core growth. Diagnostics stood apart: sales rose 17.0%, acquisitions contributed 16.5 points and core growth was 0.5%. Excluding respiratory, Diagnostics core growth was 7.0%, as respiratory testing subtracted 6.5 points. Adjusted diluted EPS was USD 2.11, against the consensus estimate of USD 1.92 and USD 1.89 a year earlier.

How Acquisitions and Tax Shaped the Reported Numbers

For Danaher (NYSE:DHR), the gap between reported and core growth in Diagnostics is acquired revenue. The release ties USD 84 million of inventory fair value adjustments to Masimo, the patient monitoring company, although it does not split the 16.5 points by deal. An inventory fair value adjustment arises because acquired stock is revalued at purchase, which lowers the profit on its first sale. Danaher excludes this from adjusted EPS, along with USD 513 million of amortisation and a USD 52 million Biotechnology facility impairment. GAAP earnings moved the other way: a discrete tax benefit of USD 263 million, mainly from releasing reserves for uncertain tax positions, added USD 0.37 per share. Net earnings therefore rose 34.5% to USD 1.2 billion, a figure that includes that one-off benefit.

Risks and What to Watch

The first risk for Danaher (NYSE:DHR) is respiratory testing, which cut 6.5 points from Diagnostics core growth and is guided as a headwind of about 150 basis points in the fourth quarter. The second is integration: acquired businesses lift reported growth but carry fair value charges and amortisation, and the facility impairment shows that capacity can also be written down. The third is execution against a higher bar, since the company guides fourth-quarter core growth excluding respiratory of 4.0% to 5.0% and an adjusted operating margin of about 29.5%. Rates add pressure on biotechnology customers, with the federal funds range at 3.75% to 4.00%. Investors should watch the Fed decision on Wednesday, October 28, 2026 and fourth-quarter results against these targets.

Where Things Stand

The answer is that Danaher (NYSE:DHR) Diagnostics sales jumped 17% because acquisitions added 16.5 points, while organic growth in the segment was 0.5% as respiratory testing fell. Group core growth of 3.0% and adjusted EPS of USD 2.11 supported a higher full-year range of USD 8.57 to USD 8.62. The next catalysts are the Fed decision on October 28, the respiratory season and fourth-quarter results. Guidance is a company forecast, not a guarantee, and this is not investment advice.